Künzel, Steffen E.
Frentzel, Dominik P.
Flesch, Leonie T. M.
Knecht, Vitus A.
Rübsam, Anne
Dreher, Felix
Schütte, Moritz
Dubrac, Alexandre
Lange, Bodo
Yaspo, Marie-Laure
Lehrach, Hans
Joussen, Antonia M.
Zeitz, Oliver
Funding for this research was provided by:
Novartis Pharma (unrestricted research grant)
Charité - Universitätsmedizin Berlin
Article History
Received: 4 March 2024
Revised: 20 May 2024
Accepted: 28 May 2024
First Online: 6 June 2024
Declarations
:
: Steffen E. Künzel: Consultant for Algeacare GmbH.Dominik Frentzel: None.Leonie Flesch: None.Vitus Knecht: None.Anne Rübsam: Consultant for Novartis and Bayer; Speaking honoria from Bayer, Novartis and Roche; Research support from Deutsche Forschungsgemeinschaft (DFG) (RU 2020/3–1).Bodo Lange: CEO and shareholder of Alacris Theranostics GmbH.Felix Dreher: Employee of Alacris Theranostics GmbH.Moritz Schuette: Employee of Alacris Theranostics GmbH.Marie-Laure Yaspo: CSO and shareholder of Alacris Theranostics GmbH.Alexandre Dubrac: None.Hans Lehrach: head of company board, and shareholder of Alacris Theranostics GmbH.Antonia M. Joussen: Consultant to and speaker honorarium from Bayer, Novartis, AbbVie, Roche. Research support from Novartis, Boehringer Ingelheim.Oliver Zeitz: Consultant for Bayer, Novartis, Allergan, Roche Omeicos, Oxular, SamChungDan Pharma, Boehringer Ingelheim; Grant support from Bayer, Novartis, Boehringer Ingelheim; Speaker honorarium from Allergan, Bayer, Novartis, Roche.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Charité University Medicine and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors.